Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

During past decades, a connection between hepatitis and the host ABO/Rh blood groups has been always under dispute, with no appropriately designed study yet. This study aimed to investigate possible association between ABO blood/Rh groups with both hepatitis B and C. In this case-control setting, 200 healthy individuals (controls), 200 patients with chronic Hepatitis-B infection (HB) and 200 patients with chronic Hepatitis-C infection (HC) were recruited from 2010 to 2013 in Tabriz Sina Hospital. ABO blood and Rh grouping was performed and the results were compared between the case and control groups. Both pair of the control and HB groups and the control and HC groups were matched for their subjects' age and sex. In the control group, 178 subjects (89%) were Rh+ and 22 subjects (11%) were Rh-. In the HB group, there were 180 Rh+ (90%) and 20 Rh- (10%) patients. In the HC group there were 168 Rh+ (84%) and 32 Rh-negative (16%) patients. Both pair of the control and HB groups (p = 0.74), as well as the control and HC groups (p = 0.14) were comparable for the status of Rh. In the control group there were 84 (42%), 32 (16%), 66 (33%) and 18 (9%) subjects with A, B, O and AB blood groups, respectively. The corresponding figures were 84 (42%), 34 (17%), 58 (29%) and 24 (12%) for the HB patients; and 80 (40%), 29 (14.5%), 85 (42.5%) and 6 (3%) for the HC patients. Comparing between the control and HB groups showed no significant difference in terms of the frequency of ABO blood groups (p = 0.70). However, with comparing the control and HC groups, the rate of O blood group was significantly higher in the HC group and concomitantly, the rate of AB blood group was significantly higher in the control group (p = 0.04). Although, there is not a significant association between ABO blood groups and HB, this association is significant between certain ABO blood groups and HC.
 ...
PMID:Association between ABO blood/rhesus grouping and hepatitis B and C: a case-control study. 2603 63

In contrast to other types of organ transplantation, liver-transplant recipients used to be considered highly resistant to donor-specific antibodies (DSAs). Consequently, most transplant programs did not consider the presence of DSAs at transplantation or during the follow-up. However, since the early 1990s, antibody-mediated pathological lesions have been recognized in ABO-incompatible liver-transplant recipients. Recent data confirm the detrimental effect of preformed and de novo DSAs in ABO-compatible liver transplantation, with inferior clinical outcomes in patients presenting with circulating antibodies. Acute antibody-mediated rejection (AMR), plasma-cell hepatitis, biliary stricture, but also long-term complications, such as chronic rejection, liver ductopenia, and graft fibrosis, are now recognized to be associated with DSAs. Moreover, some non-HLA DSAs are suspected to induce graft dysfunction. Clinical, biological, and histological patterns within AMR need to be clarified. Treatment of these complications has yet to be defined. This article summarizes recent advances concerning the impact of preformed and de novo DSAs in liver transplantation, it defines the complications associated with DSAs, and discusses the potential strategies to manage patients with such complications.
 ...
PMID:Donor-specific antibodies and liver transplantation. 2691 36

Many papers have reported on pregnancy and delivery after liver transplantation, but there have been no reports on pregnancy after ABO-incompatible liver transplantation. This paper reports the first successful pregnancy and delivery of a newborn after ABO-incompatible liver transplantation for fulminant hepatic failure. The patient was a 39-year-old female. She had an ABO-incompatible liver transplantation, donated from her husband, due to subacute fulminant hepatitis of unknown etiology. She was taking tacrolimus, methylprednisolone, and mizoribine orally for the maintenance of immunosuppression at the time of discharge. She was discharged uneventfully on postoperative day 38 without any rejection episodes. At 1 year and 6 mo after transplantation, she indicated a wish to become pregnant. Therefore, treatment with mycophenolate mofetil was interrupted at that time. After two miscarriages, she finally became pregnant and delivered transvaginally 3 years after the transplantation. All of the pregnancies were conceived naturally. The newborn was female with a birth weight of 3146 g; the Apgar scores were 9 and 10. Delivery was performed smoothly, and the newborn exhibited no malformations. The mother and the newborn were discharged uneventfully. We suggest that pregnancy is possible for recipients after ABO-incompatible liver transplantation.
 ...
PMID:First successful perinatal management of pregnancy after ABO-incompatible liver transplantation. 2821 92


<< Previous 1 2 3 4